“…In sub-Saharan Africa, nonadherence is diagnosed in 33% to 58% patients receiving ARV drugs 5,7,8 ; In Tunisia, frequencies are 27% and 65%, 9,10 while a meta-analysis in North America reports 45%. 7 There is no “gold standard” to evaluate adherence so that comparisons of frequencies are sometimes difficult.…”